Abstract
The aim of this study was to assess the effect of Coronavirus disease-19 (CoVID-19) on body and daily activity in Kurdistan Region, Iraq. This study was conducted among 320 participants using an online application. The questionnaire included items related to negative impact of CoVID-19 on daily life. ...
Read More
The aim of this study was to assess the effect of Coronavirus disease-19 (CoVID-19) on body and daily activity in Kurdistan Region, Iraq. This study was conducted among 320 participants using an online application. The questionnaire included items related to negative impact of CoVID-19 on daily life. The weight gaining included little (46 %) and severe (25 %). Sleep disturbance was less affected (24 % little and 8 % severe). The impact on daily living routines included 38 % little and 50 % severe (p= 0.04). Notably, 47 % (p = 0.001) of participants had severe deacrease in daily output (p=0.041). The quarantine and disturbed lifestyle during COVID-19 caused significant changes in body and daily activity or output in Northern Iraq.
Abstract
The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARS-CoV antibodies with associated spike ...
Read More
The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARS-CoV antibodies with associated spike protein, exerting promising implications for rapid development of vaccines and therapeutic antibodies against COVID-19. ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection; hence, it is a target for pharmacological intervention. Furthermore, designing novel monoclonal antibodies binding specifically to COVID-19 RBD is essential. A viral S proteins (TMPRSS2) was proposed for clinical use by blocking the viral intake by cell.
